JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present a corporate overview and update at the H.C. Wainwright 26th Annual Global Investment Conference on September 10th, 2024 and in the Sidoti Virtual Investor Conference on September 18-19th, 2024 and will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th, 2024 and the Lytham Partners Fall 2024 Investor Conference on October 1st, 2024.
| Event: | H.C. Wainwright 26th Annual Global Investment Conference |
| Date: | September 10, 2024 |
| Time: | 12:00 – 12:30PM EST |
| Location: | New York, NY |
| Event: | Sidoti Small-Cap Virtual Investor Conference |
| Date: | September 19, 2024 |
| Time: | 11:30AM – 12:00PM EST |
| Location: | Virtual |
| Event: | Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference |
| Date: | September 26, 2024 |
| Time: | 8:30AM – 2:30PM EST |
| Location: | New York, NY |
| Event: | Lytham Partners Fall 2024 Investor Conference |
| Date: | October 1, 2024 |
| Time: | 8:00AM – 7:00PM EST |
| Location: | Virtual |
Mr. Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your H.C. Wainwright, Sidoti, Rothschild & Co, or Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.25 |
| Daily Change: | 0.04 1.81 |
| Daily Volume: | 7,092 |
| Market Cap: | US$157.320M |
October 10, 2024 September 20, 2024 August 14, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
